Home
Corporate
Announcements
Shareholder Information
Financials
Immunotherapy
Clinical Trials
Partners
Contact Us
Share Price
Site Index
Email
Disclaimer
Virax aims to link Australia's national scientific research effort with global corporations. By adding clinical value to research science, we attempt to retain more value for Australians from the nation's scientific research efforts.

Appendix 4D - Condensed Financial Report
28 Febuary 2008

African Rainbow Minerals Limited (ARM), Anvil Mining Limited, Assmang Limited and Paladin Energy Limited Join Donor Syndicate for the Virax Southern Africa HIV Therapeutic Vaccine Project
27 Febuary 2008

Convertible Note Issue Raises $1.88 million
18 Febuary 2008

VIR201 Phase IIA Trial Results Now Published in Peer Reviewed Scientific Journal – Human Vaccines
6 Febuary 2008

Chairman’s Letter describing Fund Raising and the Corporate Strategy
30 January 2008

Technology License with Transgene: Product TG4010 Interim Results
24 January 2008

Appendix 3X & Appendix 3Z
22 January 2008

Convertible Note Issue - Amended Closing Date and Despatch Date
21 January 2008

Board Changes Completed and Extension of Rights Issue Closing Date
17 January 2008

Rights Issue Minimum Subscription Achieved
7 January 2008

Prospectus & Appointment of CEO
19 December 2007

Appendix 3B
19 December 2007

AGM Results
27 November 2007

Virax Fund Raising Proposed
27 November 2007

AGM Results and CEO Presentation
27 November 2007

Annual Report
21 September 2007

Virax Announces Grant of Key VIR201 Patent in Europe
19 September 2007

Virax Confirms Receipt of A$1m in Milestone Payments from Transgene
23 August 2007

Virax Holdings Limited
ACN 006 569 106
Suite 220, Kew Junction Tower
89 High Street, Kew
Vic 3101 Australia

Phone : +61 3 9854 6230
Facsimile : +61 3 9853 5134
E-mail : virax@virax.com.au

© Copyright Virax Holdings Limited 2001
A Blue Door Multimedia Production